Table 1:
Data from patients with newly diagnosed ovarian cancer
| Clinicopathological features | N (%) |
|---|---|
| Patients | 325 |
| Age, Mean (years) | 61.3 |
| Primary Site | |
| Ovary | 253 (78%) |
| Fallopian Tube | 14 (4%) |
| Primary Peritoneal | 58 (18%) |
| Stage | |
| I/II | 63 (19%) |
| IIIA/B | 11 (3%) |
| IIIC | 210 (65%) |
| IV | 41 (13%) |
| Grade | |
| Well differentiated | 30 (9%) |
| Moderately differentiated | 37 (11%) |
| Poorly differentiated | 214 (66%) |
| Undifferentiated | 40 (12%) |
| Not available | 4 (1%) |
| Histology | |
| Clear cell | 15 (5%) |
| Endometrioid | 16 (5%) |
| Mixed | 28 (9%) |
| Mucinous | 11 (3%) |
| Other | 26 (8%) |
| Serous | 229 (70%) |
| Debulking Status | |
| Optimal | 247 (76%) |
| Suboptimal | 61 (19%) |
| Not available | 17 (5%) |
| Residual Tumor | |
| R0a | 97 (30%) |
| Not R0 | 193 (59%) |
| Not available | 35 (11%) |
| Platinum Status | |
| Resistant/Refractory | 84 (26%) |
| Sensitive | 160 (49%) |
| Not available | 81 (25%) |
| Survival | |
| Median PFS (95% CI) | 20 months (18.2–23.9) |
| Median OS (95% CI) | 48.8 months (42.8–61.1) |
a
No gross residual tumor after surgery